Scholarlink

<p>Pheochromocytomas and paragangliomas (PPGLs) with <i>SDHB</i> mutations frequently develop metastases, but the molecular mechanisms driving this progression remain unclear. Here we show that <i>SDHB</i>-mutant metastatic PPGLs display an amplified hypermethylation signature, particularly in genes involved in neuronal differentiation, building on previous findings in <i>SDHx</i>-mutated tumors. This epigenetic shift is already detectable in benign <i>SDHB</i>-mutant tumors, suggesting early priming toward a less differentiated state. In parallel, we identify hypomethylation of genes linked to carbohydrate metabolism, notably the fructose transporter <i>SLC2A5</i>. Functional assays reveal that <i>SDHB</i> loss, hypoxia, exogenous succinate, and fructose availability promote tumor cell growth and induce cell-type–restricted, <i>SDHB</i>-dependent, induction of <i>SLC2A5</i> expression. These findings highlight the dual role of <i>SDHB</i> mutations in driving epigenetic reprogramming and metabolic adaptation, promoting tumor cell plasticity and survival under metabolic stress. By uncovering a fructose-driven metabolic vulnerability, our study provides insights into the molecular mechanisms underlying metastatic PPGLs and identifies potential therapeutic targets at the intersection of epigenetic and metabolic regulation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epigenetic and metabolic rewiring in metastatic pheochromocytomas and paragangliomas driven by SDHB mutations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月15日

查看全文
  • Tamara Cubiella,
  • Juan José Alba-Linares,
  • Jaime San-Juan-Guardado,
  • Alvaro Suarez-Priede,
  • Nerea Gómez-Suárez,
  • Maria Tous,
  • Irina Bancos,
  • Carles Villabona,
  • Teresa Serrano,
  • Isabel Tena,
  • Maribel Del Olmo,
  • Lluis Forga,
  • Nuria Valdés,
  • Mario F. Fraga,
  • María-Dolores Chiara

摘要

Pheochromocytomas and paragangliomas (PPGLs) with SDHB mutations frequently develop metastases, but the molecular mechanisms driving this progression remain unclear. Here we show that SDHB-mutant metastatic PPGLs display an amplified hypermethylation signature, particularly in genes involved in neuronal differentiation, building on previous findings in SDHx-mutated tumors. This epigenetic shift is already detectable in benign SDHB-mutant tumors, suggesting early priming toward a less differentiated state. In parallel, we identify hypomethylation of genes linked to carbohydrate metabolism, notably the fructose transporter SLC2A5. Functional assays reveal that SDHB loss, hypoxia, exogenous succinate, and fructose availability promote tumor cell growth and induce cell-type–restricted, SDHB-dependent, induction of SLC2A5 expression. These findings highlight the dual role of SDHB mutations in driving epigenetic reprogramming and metabolic adaptation, promoting tumor cell plasticity and survival under metabolic stress. By uncovering a fructose-driven metabolic vulnerability, our study provides insights into the molecular mechanisms underlying metastatic PPGLs and identifies potential therapeutic targets at the intersection of epigenetic and metabolic regulation.